Despite subsequent reductions in glycaemia, and the administration of a second dose of rapid-acting insulin 60 minutes post-exercise, all patients under 50% were protected from hypoglycaemia throughout their laboratory stay. The gene discussed is INS; the disease is Hypoglycemia.